Search

Your search keyword '"Bilgin, Yavuz M"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Bilgin, Yavuz M" Remove constraint Author: "Bilgin, Yavuz M"
213 results on '"Bilgin, Yavuz M"'

Search Results

1. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

3. Mobilization and Collection of HSC

4. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

5. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

6. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

7. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

8. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

9. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

10. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

11. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

12. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

13. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

14. Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

15. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

16. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

17. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

18. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

19. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

20. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

21. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

22. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

23. Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

24. Risk of male breast cancer after Hodgkin lymphoma

25. S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY

26. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

27. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.

28. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19:matched-paired analysis in the EPICOVIDEHA registry

29. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

30. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

31. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

32. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

33. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry.

34. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

35. Risk of male breast cancer after Hodgkin lymphoma

36. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry

37. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

38. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

39. Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

40. A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

41. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

42. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

43. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

44. T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

46. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

47. Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

48. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

49. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.

50. Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]

Catalog

Books, media, physical & digital resources